How to Calculate Systemic Vascular Resistance (SVR)

Systemic vascular resistance is calculated by taking the difference between mean arterial pressure and central venous pressure, dividing by cardiac output, and then multiplying by a conversion factor of 80 to express the result in the standard unit of dyn·s·cm⁻⁵. The formula looks straightforward, but every variable in it requires careful measurement, and the number you get carries more clinical nuance than its simplicity suggests.

The Formula and What Goes Into It

The standard SVR equation is built on a hydraulic analogy: resistance equals the pressure drop across a system divided by the flow through it. In the circulation, the pressure drop is the difference between the mean arterial pressure (MAP) at the aortic root and the central venous pressure (CVP) at the right atrium. The flow is cardiac output (CO), measured in liters per minute. Putting it together:

SVR = [(MAP − CVP) ÷ CO] × 80

The factor of 80 converts the raw result from mmHg·min/L (sometimes called Wood units or hybrid resistance units) into dyn·s·cm⁻⁵, which is the conventional unit in most clinical settings. Some centers skip the conversion and report in Wood units, so always check which unit system is being used before comparing values.

In healthy adults at rest, SVR typically falls somewhere between about 800 and 1,200 dyn·s·cm⁻⁵. Values above or below that range tell the clinical team something about the tone of the arterial tree and, indirectly, about the heart’s ability to push blood forward.

Getting the Numbers in Practice

Each variable in the formula comes from a different measurement, and each has its own sources of error.

MAP is the easiest to obtain. An arterial line gives a continuous, beat-to-beat waveform from which the monitor calculates MAP automatically. In situations where only a non-invasive blood-pressure cuff is available, MAP can be estimated from the systolic and diastolic readings using the approximation: MAP ≈ diastolic + one-third of the pulse pressure. This estimate is less precise but adequate for many bedside decisions.

CVP requires a central venous catheter, typically placed in the internal jugular or subclavian vein with its tip near the junction of the superior vena cava and right atrium. The transducer must be zeroed at the level of the right atrium (the phlebostatic axis, roughly the midaxillary line at the fourth intercostal space) to avoid positional artifacts.

CO is the most complex input. The classic method uses a pulmonary artery catheter (PAC), where a bolus of cold saline is injected and a thermistor downstream measures the temperature change over time. Modern PACs can also measure CO continuously using a thermal filament that intermittently heats blood, eliminating the need for manual bolus injections and giving a rolling average instead of a single snapshot.¹ Less invasive alternatives exist too: pulse-contour analysis devices (such as the FloTrac or PiCCO system) estimate CO from the shape of the arterial waveform, and bioreactance monitors do so entirely from chest-surface sensors.²

Does CVP Actually Matter in the Calculation?

In many ICU patients, CVP is low relative to MAP, often sitting in the range of 2 to 8 mmHg against a MAP of 65 to 90 mmHg. That makes the CVP term a small fraction of the numerator, and some clinicians wonder whether you can just ignore it and use MAP alone. A retrospective study examined exactly this question and found that dropping CVP from the equation did not dramatically change the SVR estimate in most patients. However, the same study cautioned that CVP provides clinically valuable information beyond its role in the SVR formula, such as flagging right heart failure, and therefore should not be discarded from monitoring.³

Where CVP matters most for the SVR calculation itself is in patients with significantly elevated right-sided pressures, such as those in right ventricular failure, severe tricuspid regurgitation, or massive volume overload. In these situations CVP can climb into the high teens or twenties, and omitting it would meaningfully inflate the SVR result. The safest practice is to include CVP when it is available and to note in your charting when you have substituted zero.

Indexing SVR to Body Size

Raw SVR does not account for body size, which matters when comparing patients or tracking trends in someone whose fluid status is shifting. To adjust for this, clinicians divide SVR by body surface area (BSA) to get the systemic vascular resistance index (SVRI). BSA is usually estimated using height and weight via a standard formula (the Du Bois equation is the most common). SVRI is reported in dyn·s·cm⁻⁵·m² and has its own reference range, loosely around 1,900 to 2,400 dyn·s·cm⁻⁵·m² in adults.

In obstetric hemodynamics, researchers have taken indexing a step further. One approach multiplied SVRI by heart rate to create a “stroke systemic vascular resistance index,” capturing the resistance the vasculature imposes on each individual heartbeat rather than across a full minute of output.⁴ This kind of derived variable is not standard bedside practice, but it illustrates how the basic SVR formula can be repackaged depending on the clinical question.

What High SVR Tells You

An elevated SVR usually signals that the arterioles are clamping down, either because the body’s own sympathetic nervous system is driving vasoconstriction or because a drug is doing so. The most clinically important high-SVR scenario is cardiogenic shock. When the heart’s pumping ability drops, the body tries to maintain blood pressure by constricting peripheral vessels and retaining fluid. Catecholamine release, activation of the renin-angiotensin system, and sympathetic drive all push SVR up. This initially preserves organ perfusion pressure, but the higher resistance also increases the workload on an already failing ventricle, creating a vicious cycle: the heart strains against more resistance, pumps less effectively, and the body responds by constricting further.⁵

Other causes of high SVR include hypovolemia (where a shrinking circulating volume triggers compensatory vasoconstriction), hypothermia, and certain drugs like high-dose vasopressors. In all of these, the SVR number helps clinicians decide whether to reduce afterload with a vasodilator, support the heart with an inotrope, or address the underlying trigger.

What Low SVR Tells You

A low SVR points to pathological vasodilation. Sepsis is the most common cause in the ICU. Inflammatory mediators relax vascular smooth muscle, causing the arterial tree to dilate widely. CO often rises as a compensatory response, but the vasodilation can outpace the cardiac compensation, dropping blood pressure despite a normal or even elevated cardiac output. The combination of high CO and low SVR is the hemodynamic fingerprint of distributive (vasodilatory) shock.

One study that examined patients with low SVR in an ICU setting defined it using the formula SVR (dyn·s·cm⁻⁵) = (80 × MAP) / CO, noting that when transcribed to human hemodynamics, the pressure gradient between MAP and CVP divided by flow gives the resistance value.⁶ Other causes of low SVR include anaphylaxis, neurogenic shock (where spinal cord injury removes sympathetic tone), liver failure, and certain drug effects such as epidural anesthesia or overdose of vasodilators.

Drugs That Shift SVR and Why It Matters

Pharmacological manipulation of SVR is central to critical care. When SVR is dangerously low, vasopressors are used to tighten the arterial tree. Norepinephrine, the first-line agent in most septic shock protocols, acts primarily on alpha-1 and alpha-2 receptors to constrict arterioles while also providing some beta-1 stimulation to the heart. Phenylephrine, by contrast, is a selective alpha-1 agonist that targets larger arterioles and has essentially no effect on terminal arterioles.⁷ This distinction matters because the site of vasoconstriction affects not just SVR as a number but also regional blood flow distribution.

When SVR is too high and the heart is struggling against excessive afterload, vasodilators come into play. Sodium nitroprusside has been studied extensively in this role. In patients with chronic ischemic heart disease and heart failure, nitroprusside lowered total SVR from roughly 1,590 to 1,310 dyn·s·cm⁻⁵ while also relaxing veins, which reduced preload.⁸ The net effect was improved ventricular performance with less energy consumption by the heart. Phentolamine, another vasodilator, produced a comparable drop in SVR (from about 1,475 to 1,200 dyn·s·cm⁻⁵), whereas sublingual nitroglycerin did not significantly change SVR, acting instead primarily on the venous capacitance side.⁹ This is a meaningful clinical distinction: if the goal is specifically to lower SVR and reduce the resistance the ventricle pumps against, nitroglycerin alone is not the right tool.

Nitroprusside also reduces the pulsatile components of vascular load, not just the steady-state resistance captured by the SVR formula. In heart failure patients, even small doses brought down left ventricular end-diastolic pressure by about 44% and increased stroke volume by about 20% within 60 to 90 seconds.¹⁰ The speed of that response illustrates why continuous hemodynamic monitoring matters when titrating vasoactive drugs.

Why SVR Is an Imperfect Measure of Afterload

One of the most persistent misconceptions about SVR is that it equals left ventricular afterload. It does not. SVR captures the steady-state opposition to flow across the arterial tree, which is essentially the tone of the peripheral arterioles. True left ventricular afterload, the internal load on the muscle fibers during systole, depends on more than arteriolar tone. It includes chamber pressure, ventricular size, wall thickness, aortic compliance, and the timing of reflected pressure waves. A measure called end-systolic wall stress captures these factors much more faithfully. Because SVR reflects only one piece of the afterload puzzle, discordant changes between SVR and true afterload can occur during drug treatment: SVR might drop while actual ventricular wall stress stays the same, or vice versa.¹¹

A related limitation applies to pulmonary vascular resistance (PVR), which is calculated the same way but for the pulmonary circuit. PVR, like SVR, describes only the steady-state relationship between pressure and flow and can underestimate total power dissipation by as much as half, because it ignores oscillatory and kinetic energy components.¹² These limitations do not make SVR useless. They make it one data point in a hemodynamic profile that should always be interpreted alongside filling pressures, cardiac output trends, and clinical exam findings, not treated as a standalone verdict.

Non-Invasive Approaches to Estimating SVR

Not every patient has a pulmonary artery catheter or even a central line, and the trend in hemodynamic monitoring has been steadily toward less invasive methods. Doppler echocardiography offers one route. In one validated approach, researchers used the ratio of peak mitral regurgitant velocity to the left ventricular outflow tract velocity-time integral as a non-invasive surrogate for SVR.¹³ This method works well when mitral regurgitation is present and the Doppler signals are clean, but it cannot be applied in every patient.

A simpler Doppler-derived estimate, sometimes called eSVR, uses the ratio of systolic blood pressure to the left ventricular outflow tract velocity-time integral. One large cohort study used this eSVR measure and found it was independently associated with cardiovascular outcomes, suggesting that even a rough echocardiographic approximation carries prognostic information.¹⁴

Even further along the non-invasive spectrum, finger photoplethysmography (the light-based sensor used in pulse oximeters) has been explored as a source for SVR estimation. A multivariate regression model built from photoplethysmogram waveform features achieved a bias of roughly −0.87 dyn·s·cm⁻⁵ with a precision of about ±412 dyn·s·cm⁻⁵ compared with invasive reference values.¹⁵ That precision window is too wide for high-stakes titration decisions, but for screening or trend monitoring in lower-acuity settings, it may eventually prove useful.

Pediatric and Neonatal Considerations

Children are not small adults, and their SVR reference ranges reflect that. Normal SVR values shift with age: neonates typically fall in the range of about 900 to 1,400 dyn·s·cm⁻⁵, infants around 800 to 1,200, and older children and adolescents roughly 700 to 1,200.¹⁶ These ranges are approximate and vary with the measurement method used, so tracking individual trends over time matters more than comparing a single value to a population average.

In the neonatal ICU, SVR is trickier still. Gestational age and birth weight both affect baseline SVR, with resistance decreasing as both increase. A study using electrical cardiometry in hemodynamically stable neonates confirmed this pattern and provided gestational-age and birth-weight-based nomograms with good statistical fit.¹⁷ The clinical takeaway is that a preterm infant’s “normal” SVR is higher than a term infant’s, and using adult formulas or reference ranges without adjustment is misleading. Indexing to BSA is especially important in pediatrics, where body size varies enormously within a single ward.

Common Calculation Mistakes at the Bedside

The formula is simple enough to compute by hand or in a spreadsheet, but errors creep in with surprising regularity. The most frequent is a unit mismatch. If you forget the ×80 conversion factor, you get a number in Wood units that looks alarmingly low when compared to a reference range given in dyn·s·cm⁻⁵. Conversely, applying the conversion factor twice (which can happen when a monitoring system already reports in dyn·s·cm⁻⁵ and a resident manually recalculates) produces a grossly inflated result.

Another common issue is using a cuff blood pressure for MAP in a patient whose waveform is heavily damped or who is on high-dose vasopressors. Non-invasive cuffs tend to underread systolic and overread diastolic pressure in hypotensive patients, which can distort the estimated MAP and therefore the SVR. When vasoactive drugs are being titrated, an arterial line is the more reliable source.

Finally, cardiac output values are themselves estimates with confidence intervals. Thermodilution measurements can vary by 10 to 15 percent between sequential boluses depending on injection technique and timing relative to the respiratory cycle. Because CO sits in the denominator of the SVR equation, even modest measurement error gets amplified. A 10 percent overestimate of CO yields roughly a 10 percent underestimate of SVR. Averaging multiple CO measurements and recalculating helps, as does using continuous thermodilution when available.

When SVR Matters Most and When It Does Not

SVR is most useful as a trend monitor and a tool for distinguishing shock subtypes at the bedside. A patient in shock with a high SVR and low CO likely has a cardiogenic or hypovolemic picture, while one with a low SVR and preserved or high CO fits a distributive pattern. That distinction directly changes the treatment: the first patient may need afterload reduction or an inotrope, while the second needs a vasopressor. In both scenarios, the SVR number guides the drug choice and helps the team gauge whether their intervention is working.

Where SVR is less helpful is in outpatient or chronic disease management. You will not see your primary care doctor ordering an SVR measurement at a routine checkup. The test requires invasive or semi-invasive hemodynamic data that are only practical in an ICU, operating room, or cardiac catheterization lab. Even in those settings, SVR is most valuable when integrated with other parameters: filling pressures, mixed venous oxygen saturation, lactate, and the clinical picture. Treating a number in isolation, chasing a “normal” SVR without considering what the heart and the tissues are actually doing, is one of the classic traps in hemodynamic management.